New analyses from FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF (opens original article in a new tab)

New analyses from FIBRONEER trials indicate that nerandomilast may significantly improve survival for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), with modeling suggesting up to 5.4 years longer survival for IPF and 3.3 years for PPF compared to no therapy.

• New analyses from FIBRONEER trials suggest nerandomilast may improve survival in IPF and PPF.
• Modeling predicts up to 5.4 years longer survival for IPF patients and 3.3 years for PPF patients with nerandomilast.
• Nerandomilast showed slowed lung function decline in clinical trials, with a 59% reduction in death risk in monotherapy.